GLP-1 Receptor Activation and Epac2 Link Atrial Natriuretic Peptide Secretion to Control of Blood Pressure

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2013 Apr 2

PMID 23542788

Citations 209

Authors

Minsuk Kim

Mathew J Platt

Tadao Shibasaki

Susan E Quaggin

Peter H Backx

Susumu Seino

Jeremy A Simpson

Daniel J Drucker

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists exert antihypertensive actions through incompletely understood mechanisms. Here we demonstrate that cardiac Glp1r expression is localized to cardiac atria and that GLP-1R activation promotes the secretion of atrial natriuretic peptide (ANP) and a reduction of blood pressure. Consistent with an indirect ANP-dependent mechanism for the antihypertensive effects of GLP-1R activation, the GLP-1R agonist liraglutide did not directly increase the amount of cyclic GMP (cGMP) or relax preconstricted aortic rings; however, conditioned medium from liraglutide-treated hearts relaxed aortic rings in an endothelium-independent, GLP-1R-dependent manner. Liraglutide did not induce ANP secretion, vasorelaxation or lower blood pressure in Glp1r(-/-) or Nppa(-/-) mice. Cardiomyocyte GLP-1R activation promoted the translocation of the Rap guanine nucleotide exchange factor Epac2 (also known as Rapgef4) to the membrane, whereas Epac2 deficiency eliminated GLP-1R-dependent stimulation of ANP secretion. Plasma ANP concentrations were increased after refeeding in wild-type but not Glp1r(-/-) mice, and liraglutide increased urine sodium excretion in wild-type but not Nppa(-/-) mice. These findings define a gut-heart GLP-1R-dependent and ANP-dependent axis that regulates blood pressure.

Citing Articles

Postprandial variability of novel heart failure biomarkers in Fontan patients compared to healthy volunteers.

Hauser J, Muthurangu V, Pandya B, Michel-Behnke I, Taylor A, Demyanets S Int J Cardiol Congenit Heart Dis. 2025; 3:100127.

PMID: 40061029 PMC: 11890058. DOI: 10.1016/j.ijcchd.2021.100127.

Glucagon-Like Peptide-1 Links Ingestion, Homeostasis, and the Heart.

Krieger J, Daniels D, Lee S, Mastitskaya S, Langhans W Compr Physiol. 2025; 15(1):e7.

PMID: 39887844 PMC: 11790259. DOI: 10.1002/cph4.7.

Unraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism.

Narongkiatikhun P, Choi Y, Hampson H, Gotzamanis J, Zhang G, van Raalte D Kidney Int Rep. 2024; 9(12):3386-3402.

PMID: 39698345 PMC: 11652104. DOI: 10.1016/j.ekir.2024.09.019.

Association between ideal cardiovascular health and bowel conditions among US adults.

Wang Y, Wang Z Front Nutr. 2024; 11:1473531.

PMID: 39574525 PMC: 11580258. DOI: 10.3389/fnut.2024.1473531.

Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.

Raza F, Altaf R, Bashir T, Asghar F, Altaf R, Tousif S Medicine (Baltimore). 2024; 103(44):e40364.

PMID: 39496023 PMC: 11537668. DOI: 10.1097/MD.0000000000040364.

References

Carraro-Lacroix L, Malnic G, Girardi A . Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009; 297(6):F1647-55. DOI: 10.1152/ajprenal.00082.2009. View

Moro C, Crampes F, Sengenes C, de Glisezinski I, Galitzky J, Thalamas C . Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J. 2004; 18(7):908-10. DOI: 10.1096/fj.03-1086fje. View

Fonseca V . Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol. 2011; 108(3 Suppl):52B-8B. DOI: 10.1016/j.amjcard.2011.03.016. View

Drucker D, Dritselis A, Kirkpatrick P . Liraglutide. Nat Rev Drug Discov. 2010; 9(4):267-8. DOI: 10.1038/nrd3148. View

Winquist R, Faison E, Waldman S, Schwartz K, Murad F, Rapoport R . Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci U S A. 1984; 81(23):7661-4. PMC: 392208. DOI: 10.1073/pnas.81.23.7661. View

Bordicchia M, Liu D, Amri E, Ailhaud G, Dessi-Fulgheri P, Zhang C . Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012; 122(3):1022-36. PMC: 3287224. DOI: 10.1172/JCI59701. View

Sivertsen J, Rosenmeier J, Holst J, Vilsboll T . The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012; 9(4):209-22. DOI: 10.1038/nrcardio.2011.211. View

Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W . Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012; 61(4):888-96. PMC: 3314347. DOI: 10.2337/db11-1073. View

Ballermann B . A highly sensitive radioreceptor assay for atrial natriuretic peptide in rat plasma. Am J Physiol. 1988; 254(1 Pt 2):F159-63. DOI: 10.1152/ajprenal.1988.254.1.F159. View

10.

Drucker D, Philippe J, Mojsov S, Chick W, Habener J . Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987; 84(10):3434-8. PMC: 304885. DOI: 10.1073/pnas.84.10.3434. View

11.

Lonborg J, Vejlstrup N, Kelbaek H, Botker H, Kim W, Mathiasen A . Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2011; 33(12):1491-9. DOI: 10.1093/eurheartj/ehr309. View

12.

Ropero A, Soriano S, Tuduri E, Marroqui L, Tellez N, Gassner B . The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. Endocrinology. 2010; 151(8):3665-74. DOI: 10.1210/en.2010-0119. View

13.

Fonseca V, Zinman B, Nauck M, Goldfine A, Plutzky J . Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am J Med. 2010; 123(7):S2-S10. DOI: 10.1016/j.amjmed.2010.04.002. View

14.

Scrocchi L, Brown T, MacLusky N, Brubaker P, AUERBACH A, Joyner A . Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996; 2(11):1254-8. DOI: 10.1038/nm1196-1254. View

15.

Padmanabhan S, Newton-Cheh C, Dominiczak A . Genetic basis of blood pressure and hypertension. Trends Genet. 2012; 28(8):397-408. DOI: 10.1016/j.tig.2012.04.001. View

16.

Goldfine A . Assessing the cardiovascular safety of diabetes therapies. N Engl J Med. 2008; 359(11):1092-5. DOI: 10.1056/NEJMp0805758. View

17.

Crajoinas R, Oricchio F, Pessoa T, Pacheco B, Lessa L, Malnic G . Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011; 301(2):F355-63. DOI: 10.1152/ajprenal.00729.2010. View

18.

Sambrano G, Fraser I, Han H, Ni Y, OConnell T, Yan Z . Navigating the signalling network in mouse cardiac myocytes. Nature. 2002; 420(6916):712-4. DOI: 10.1038/nature01306. View

19.

Richards A, Nicholls M, Espiner E, Ikram H, Yandle T, Joyce S . Effects of alpha-human atrial natriuretic peptide in essential hypertension. Hypertension. 1985; 7(5):812-7. DOI: 10.1161/01.hyp.7.5.812. View

20.

Golpon H, Puechner A, Welte T, V Wichert P, Feddersen C . Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001; 102(2-3):81-6. DOI: 10.1016/s0167-0115(01)00300-7. View